Maggie L. Shaw

Enrique Ocio, MD, PhD, Hematology Department head, Marqués de Valdecilla University Hospital, Santander, Spain, discussed the convenience seen in subcutaneous isatuximab.

Thanos Zomas, MD, global medical lead for lymphoma and leukemia and for the Adcetris Program, Takeda Oncology, discussed results of the ECHELON-1 trial.

Hope S. Rugo, MD, FASCO, professor of medicine and director, Breast Oncology and Clinical Trials Education, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, said PALOMA-2 results don’t match what she has seen in practice.

Although melanoma incidence has been reported in Europe overall for the past several decades, specific numbers on the cancer’s incidence in Finland, as well as disease trends, have remained unknown.

Joel Neal, MD, PHD, associate professor, Division of Oncology, Stanford Cancer Institute, discussed phase 1b results in COSMIC-021 in non-small cell lung cancer.

In part 2 of our interview with Anne McCall, PhD, provost and senior vice president for academic affairs at Xavier University of Louisiana, she discusses in greater detail the university’s 3-year partnership with Takeda, in particular how the directions it goes in will be influenced by the history of unequal health care delivery in the state.

Kim A. Reiss, MD, assistant program director, assistant professor of medicine, Hospital of the University of Pennsylvania, Philadelphia, discusses 2 abstracts presented during ASCO.

Randall A. Oyer, MD, medical director of the Ann B. Barshinger Cancer Institute, medical director of oncology, and medical director of the Cancer Risk Evaluation Program, Lancaster General Health, discusses recommendations to improve diversity in clinical trials.

This new study investigated the ability of a multiparametric model to calculate risk of eosinophilic chronic rhinosinusitis with nasal polyps (ECRSwNP) by comparing its clinical characteristics with noneosinophilic CRSwNP.

Several measures of hemodynamic capacity were improved in this study that evaluated sacubitril/valsartan use for heart failure with preserved ejection fraction and pulmonary hypertension (HFpEF-PH).

This new study investigated the impact of overly restrictive salt-intake guidelines on patients living with heart failure with preserved ejection fraction (HFpEF), because despite accounting for half of all HF cases, this patient population is often excluded from studies in the space.

Three methods of cosmetic surgery—local skin flap, full thickness skin graft, and secondary intention—were evaluated for their scarring risk following Mohs microscopic surgery on the distal third of the nose.

Anne McCall, PhD, provost and senior vice president for academic affairs at Xavier University of Louisiana, in New Orleans, delves into the new partnership between the university and Takeda.

New date from the KEYNOTE-716 trial show distant metastasis-free survival benefit from pembrolizumab use in melanoma.

Conflicting prior study results on the effectiveness of calprotectin expression as a protective or pathologic response among persons with chronic rhinosinusitis with nasal polyps (CRSwNP) spurred this new investigation.

A Belgian study compared exercise performance before and after COVID-19 lockdown measures were swiftly implemented in the country among patients with preexisting pulmonary arterial hypertension (PAH).

Although approved for use among patients with severe or refractory asthma, few studies have investigated its effectiveness among patients with comorbid mild to moderate asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).

Few data exist on how right ventricular fractional area change (RVFAC) may contribute to outcomes among patients hospitalized for heart failure, so that potential relationship was investigated in this new study from Japan.

Abstracts presented at this year's American Society of Clinical Oncology Annual meeting detailed the financial hardships many patients with cancer face, including those related to high-deductible health plans and clinical trial participation.

Investigators from Ghana evaluated cardiac abnormalities among persons living with HIV who were or were not on highly active antiretroviral treatment.

Knowing that insulin requirements vary widely among persons who have type 1 diabetes, 3-month effectiveness of the Omnipod 5 Automated Insulin Delivery System was evaluated across 6 daily insulin doses.

Using chronotropic response as a reference, study authors from Japan investigated the potential influence of exercise-induced heart rate on cardiac output reserve and exercise capacity among a cohort of patients with heart failure with preserved ejection fraction (HFpEF).

Investigators from Toronto compared morbidity and mortality outcomes among patients with acute decompensated heart failure (ADHF) before and during the COVID-19 pandemic.

Patients with iCCA, particularly those whose disease progresses following first-line chemotherapy, have limited overall treatment options. Data presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting show that patients may soon have a new agent to fight this rare cancer in futibatinib (Taiho Oncology), an FGFR inhibitor.